Frazier Healthcare Partners announced the planned addition of Albert Cha, M.D., Ph.D. as Managing Partner on the Life Sciences team. He has over 20 years of experience investing in public and private biopharmaceutical and medical device companies.
Dr. Cha was previously a Managing Partner at Vivo Capital. He currently serves on the boards of Ascendis Pharma A/S (NASDAQ: ASND) and KalVista Pharmaceuticals (NASDAQ: KALV), and has served on the boards of Aclaris Therapeutics (NASDAQ: ACRS), Biohaven Pharma (NYSE: BHVN), Menlo Therapeutics (NASDAQ: MNLO), Sierra Oncology (NASDAQ: SRRA), Ceptaris Therapeutics (acquired by Actelion), Neomend (acquired by Bard), Vicept Therapeutics (acquired by Allergan), Bioform Medical (NASDAQ: BFRM, acquired by Merz), Biodel (NASDAQ: BIOD), and NextWave Pharmaceuticals (acquired by Pfizer).
Dr. Cha is a co-founder of the annual Dermatology Summit and Dermatology Innovation Forum. He also worked at Oracle Corporation in pharmaceutical consulting and at the Palo Alto VA Hospital as a biomedical engineer.
Dr. Cha received his B.S. and M.S. in Electrical Engineering from Stanford University. He subsequently completed the Medical Scientist Training Program at UCLA School of Medicine, where he received his M.D. and Ph.D. in Neuroscience.
“We are excited to welcome Albert to the Life Sciences team,” said Patrick Heron, Managing Partner at Frazier. “He is a highly experienced investor who will be critical in helping us continue to identify attractive public and private investments.”
About Frazier Healthcare Partners
Founded in 1991, Frazier Healthcare Partners is a leading provider of growth and venture capital to healthcare companies. With nearly $4.8 billion total capital raised, Frazier has invested in over 200 companies, with investment types ranging from company creation and venture capital to buyouts of profitable lower-middle market companies. The firm’s Growth Buyout team invests in healthcare and pharmaceutical services, medical products and related sectors. The Life Sciences team invests in therapeutics and related areas that are addressing unmet medical needs through innovation. Frazier has offices in Seattle, WA and Menlo Park, CA, and invests broadly across the US, Canada, and Europe.
For more information about Frazier Healthcare Partners, visit the company's website at http://www.frazierhealthcare.com.